Nine promising small molecule drug discovery companies have raised funding in the last year, with Ascentage Pharma and 858 Therapeutics leading the charge in cancer treatment. Ascentage Pharma’s most advanced candidate, olverembatinib, has been cleared in China for certain patients with chronic myeloid leukemia and is in phase 3 trials for multiple cancer indications. Meanwhile, 858 Therapeutics is developing a PARG inhibitor called ETX-19477, which is in a phase 1 trial for solid tumors.
Forecast for 6 months: Ascentage Pharma and 858 Therapeutics are expected to announce positive trial results for their respective cancer treatments, leading to increased investor interest and potential partnerships.
Forecast for 1 year: The small molecule drug discovery market is expected to experience significant growth, with Ascentage Pharma and 858 Therapeutics emerging as leaders in the field. Regulatory approvals for their treatments are likely to be granted within the next 12 months.
Forecast for 5 years: The use of small molecule drugs in cancer treatment is expected to become the standard of care, with Ascentage Pharma and 858 Therapeutics playing a key role in shaping the market. New companies are likely to enter the space, and the market is expected to reach $10 billion in revenue.
Forecast for 10 years: The development of personalized medicine using small molecule drugs is expected to revolutionize cancer treatment, with Ascentage Pharma and 858 Therapeutics at the forefront of this innovation. The market is expected to reach $50 billion in revenue, and new therapeutic areas are likely to be targeted.
